Toward patient-centered, phenotype-driven care for dry eye disease: a review of advances in artificial tear formulation
Expert Review of Ophthalmology, cilt.21, sa.5, ss.451-468, 2026 (ESCI, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 21 Sayı: 5
- Basım Tarihi: 2026
- Doi Numarası: 10.1080/17469899.2026.2728014
- Dergi Adı: Expert Review of Ophthalmology
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Chemical Abstracts Core, CINAHL, EMBASE, Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Sayfa Sayıları: ss.451-468
- Anahtar Kelimeler: artificial tears, Dry eye disease, osmoprotectants, personalized care, tear replenishment, tear supplementation, TFOS DEWS III
- Ankara Üniversitesi Adresli: Evet
Özet
Introduction: The tear film is part of the ocular surface and forms a highly complex interface between the corneal and conjunctival epithelium and the environment. As a key refracting surface, it is essential in maintaining clear vision, as well as supporting the health and integrity of the entire ocular surface. Areas covered: This review describes the structure and stability of the tear film, a complex, dynamic, trilayered combination of mucins, aqueous components, and lipids. It discusses how loss of this stability leads to inflammation, ocular surface damage, eye dryness, and discomfort that can significantly impair vision and quality of life. Finally, it summarizes the current and future state of dry eye disease (DED) management. Over-the-counter artificial tear eye drops remain a therapeutic cornerstone and represent part of first-line therapy for most patients. Artificial tears are typically multi-component formulations and differ in their active ingredients, preservative content, electrolytes, vehicle formulation, and concentration and consistency. Expert opinion: A nuanced, phenotype-driven approach to artificial tear selection, rather than viewing tear substitutes as interchangeable therapies, is necessary. Clinicians should aim to align formulation characteristics with disease etiology, symptom profile, lifestyle factors, and patient preferences to achieve more specific targeted disease management.